SRI-29329 is a potent, specific CDC-like kinase (CLK) inhibitor. It acts by targeting CLK1, 2 and 4, respectively. References: Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412. doi: 10.1016/j.bmcl.2016.12.056. Epub 2016 Dec 24. Erratum in: Bioorg Med Chem Lett. 2017 Mar 15;27(6):1488-1489. PubMed PMID: 28049589; PubMed Central PMCID: PMC5295499.

纯度：≥98%

CAS：2086809-58-5